Is representation enough or should we be targeting equitable inclusion?
Nature Reviews Clinical Oncology, Published online: 11 April 2022; doi:10.1038/s41571-022-00635-zTo achieve health equity, we advocate for the overrepresentation of particular racial and ethnic minority groups so that analyses of group-specific treatment effects can be optimally powered. A paradigm shift is needed across multiple stakeholders, as well as in the engagement of community programmes, the role of investigators from racial and ethnic minority backgrounds and clinical trial regulations. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 11, 2022 Category: Cancer & Oncology Authors: Scarlett Lin Gomez Chiaojung Jillian Tsai Source Type: research
Author Correction: Clinical relevance of tumour-associated macrophages
Nature Reviews Clinical Oncology, Published online: 06 April 2022; doi:10.1038/s41571-022-00632-2Author Correction: Clinical relevance of tumour-associated macrophages (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 6, 2022 Category: Cancer & Oncology Authors: Mikael J. Pittet Olivier Michielin Denis Migliorini Source Type: research
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome
Nature Reviews Clinical Oncology, Published online: 01 April 2022; doi:10.1038/s41571-022-00619-zThe tumour microenvironment includes various diverse immune cell types, each of which might influence tumour progression and response to treatment, particularly with immunotherapies. These cell types include different subtypes of B lymphocytes, which are often associated with tertiary lymphoid structures (TLS) and can have pro-tumour or anti-tumour effects, either through their classical function in antibody production and antigen presentation or other mechanisms. Herein, Fridman et al. discuss the phenotypic heterogeneity of i...
Source: Nature Reviews Clinical Oncology - April 1, 2022 Category: Cancer & Oncology Authors: Wolf H. Fridman Maxime Meylan Florent Petitprez Cheng-Ming Sun Antoine Italiano Catherine Saut ès-Fridman Source Type: research
Should the control arms of randomized trials have an expiry date?
Nature Reviews Clinical Oncology, Published online: 01 April 2022; doi:10.1038/s41571-022-00624-2Randomized controlled trials (RCTs) are conducted when clinical equipoise between treatment options exists. However, some RCTs in patients with non-small-cell lung cancer continue to use chemotherapy as the control arm several years after chemotherapy was proven inferior to anti-PD-1 antibodies. Here, we highlight why the justifications for using an inferior treatment in the control arm are invalid and offer solutions that are applicable across tumour types. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 1, 2022 Category: Cancer & Oncology Authors: Adi Kartolo Bishal Gyawali Source Type: research
T-DXd improves PFS versus T-DM1
Nature Reviews Clinical Oncology, Published online: 31 March 2022; doi:10.1038/s41571-022-00629-xT-DXd improves PFS versus T-DM1 (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 31, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
CAR T cells show promise in the frontline for high-risk LBCL
Nature Reviews Clinical Oncology, Published online: 31 March 2022; doi:10.1038/s41571-022-00628-yCAR T cells show promise in the frontline for high-risk LBCL (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 31, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
Clinical relevance of tumour-associated macrophages
Nature Reviews Clinical Oncology, Published online: 30 March 2022; doi:10.1038/s41571-022-00620-6The interaction of tumour-associated macrophages (TAMs) with cancer and stromal cells in the tumour microenvironment enables and sustains most of the hallmarks of cancer. The authors of this Review examine the diversity of TAMs in various cancer indications, which is being revisited with the advent of single-cell technologies, and discuss the functional roles of different TAM states, the prognostic and predictive value of TAM-related signatures as well as approaches involving TAMs that are currently being or will soon be tested...
Source: Nature Reviews Clinical Oncology - March 30, 2022 Category: Cancer & Oncology Authors: Mikael J. Pittet Olivier Michielin Denis Migliorini Source Type: research
Improving breast cancer risk prediction with epigenetic risk factors
Nature Reviews Clinical Oncology, Published online: 29 March 2022; doi:10.1038/s41571-022-00622-4Over the past decade, iterative improvements to models predicting breast cancer risk have primarily come from new information about genetic risk factors and improvements to mammogram-based risk scores. Epigenetic risk factors offer some potential to further improve risk stratification. However, the recently developed DNA methylation score (the WID-BC index) is not yet convincing for predicting breast cancer risk. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 29, 2022 Category: Cancer & Oncology Authors: Melissa C. Southey Pierre-Antoine Dugu é Source Type: research
Reply to ‘HPV-associated oropharyngeal cancer — discussion points’
Nature Reviews Clinical Oncology, Published online: 28 March 2022; doi:10.1038/s41571-022-00627-zReply to ‘HPV-associated oropharyngeal cancer — discussion points’ (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 28, 2022 Category: Cancer & Oncology Authors: Matt Lechner Jacklyn Liu Liam Masterson Tim R. Fenton Source Type: research
Abundant circulating lipids — a new opportunity for NSCLC detection?
Nature Reviews Clinical Oncology, Published online: 28 March 2022; doi:10.1038/s41571-022-00621-5Non-small-cell lung cancer (NSCLC) is a growing public-health threat, with one of the highest mortality risks among non-communicable diseases. Now, researchers have developed a diagnostic tool for NSCLC by mass spectrometry of a targeted panel of lipids. Herein, we discuss key aspects that could facilitate the clinical implementation of this and similar tools in other fields of application. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 28, 2022 Category: Cancer & Oncology Authors: Markus R. Wenk Hyungwon Choi Source Type: research
HPV-associated oropharyngeal cancer — discussion points
Nature Reviews Clinical Oncology, Published online: 28 March 2022; doi:10.1038/s41571-022-00626-0HPV-associated oropharyngeal cancer — discussion points (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 28, 2022 Category: Cancer & Oncology Authors: Peter Goon Holger Sudhoff Source Type: research
Radioiodine can be omitted in low-risk disease
Nature Reviews Clinical Oncology, Published online: 24 March 2022; doi:10.1038/s41571-022-00625-1Radioiodine can be omitted in low-risk disease (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 24, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
The emerging role of photoacoustic imaging in clinical oncology
Nature Reviews Clinical Oncology, Published online: 23 March 2022; doi:10.1038/s41571-022-00615-3Photoacoustic imaging is a novel imaging technique that provides scalably high levels of spatial resolution at rapid acquisition speed, without the need for radiation or exogenous contrast agents. In this Review, the authors describe the emerging role of this technology in the screening, diagnosis and management of patients with cancer, and provide an overview of the future implementation of this technology. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 23, 2022 Category: Cancer & Oncology Authors: Li Lin Lihong V. Wang Source Type: research
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Nature Reviews Clinical Oncology, Published online: 23 March 2022; doi:10.1038/s41571-022-00623-3Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 23, 2022 Category: Cancer & Oncology Authors: Michael Weller Martin van den Bent Matthias Preusser Emilie Le Rhun J örg C. Tonn Giuseppe Minniti Martin Bendszus Carmen Balana Olivier Chinot Linda Dirven Pim French Monika E. Hegi Asgeir S. Jakola Michael Platten Patrick Roth Roberta Rud à Susan Shor Source Type: research
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
Nature Reviews Clinical Oncology, Published online: 22 March 2022; doi:10.1038/s41571-022-00607-3Chimeric antigen receptor T cells have revolutionized the treatment of patients with certain haematological malignancies. Nonetheless, an optimal approach to lymphodepleting chemotherapy and/or bridging therapies has yet to be defined in patients receiving these agents. In this Review, the authors describe the various lymphodepletion and/or bridging therapy strategies used, and highlight the need for prospective comparisons in order to determine the safest and most effective approach. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 22, 2022 Category: Cancer & Oncology Authors: Leila Amini Sara K. Silbert Shannon L. Maude Loretta J. Nastoupil Carlos A. Ramos Renier J. Brentjens Craig S. Sauter Nirali N. Shah Mohamed Abou-el-Enein Source Type: research
